Quiroz, Ryan V.; Reutershan, Michael H.; Schneider, Sebastian E.; Sloman, David; Lacey, Brian M.; Swalm, Brooke M.; Yeung, Charles S.; Gibeau, Craig; Spellman, Daniel S.; Rankic, Danica A.; Chen, Dapeng; Witter, David; Linn, Doug; Munsell, Erik; Feng, Guo; Xu, Haiyan; Hughes, Jonathan M. E.; Lim, Jongwon; Sauri, Josep; Geddes, Kristin; Wan, Murray; Mansueto, My Sam; Follmer, Nicole E.; Fier, Patrick S.; Siliphaivanh, Phieng; Daublain, Pierre; Palte, Rachel L.; Hayes, Robert P.; Lee, Sandra; Kawamura, Shuhei; Silverman, Steven; Sanyal, Sulagna; Henderson, Timothy J.; Ye, Yingchun; Gao, Yuanwei; Nicholson, Benjamin; Machacek, Michelle R. published an article about the compound: Bis(norbornadiene)rhodium (I) tetrafluoroborate( cas:36620-11-8,SMILESS:[F-][B+3]([F-])([F-])[F-].C12=C3[Rh+]14567(C8=C5C9C6=C7C8C9)C%10=C4C2CC3%10 ).Computed Properties of C14H8BF4Rh. Aromatic heterocyclic compounds can be classified according to the number of heteroatoms or the size of the ring. The authors also want to convey more information about this compound (cas:36620-11-8) through the article.
Protein arginine methyltransferase 5 (PRMT5) is a type II arginine methyltransferase that catalyzes the post-translational sym. dimethylation of protein substrates. PRMT5 plays a critical role in regulating biol. processes including transcription, cell cycle progression, RNA splicing, and DNA repair. As such, dysregulation of PRMT5 activity is implicated in the development and progression of multiple cancers and is a target of growing clin. interest. Described herein are the structure-based drug designs, robust synthetic efforts, and lead optimization strategies toward the identification of two novel 5,5-fused bicyclic nucleoside-derived classes of potent and efficacious PRMT5 inhibitors. Utilization of compound docking and strain energy calculations inspired novel designs, and the development of flexible synthetic approaches enabled access to complex chemotypes with five contiguous stereo-centers. Addnl. efforts in balancing bioavailability, solubility, potency, and CYP3A4 inhibition led to the identification of diverse lead compounds with favorable profiles, promising in vivo activity, and low human dose projections.
The article 《The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer》 also mentions many details about this compound(36620-11-8)Computed Properties of C14H8BF4Rh, you can pay attention to it, because details determine success or failure
Reference:
Quinuclidine – Wikipedia,
Quinuclidine | C7H13N | ChemSpider